ArticleCell communication and signaling : CCS2025
The endonuclease activity of MCPIP1 controls the neoplastic transformation of epithelial cells via the c-Met/CD44 axis.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The RNase activity of MCPIP1 is essential for regulating cellular homeostasis, proliferation, and tumorigenesis. Our study elucidates the effects of downregulation of MCPIP1 expression and an RNase-inactivating mutation (D141N) on normal epithelial kidney cells, indicating that MCPIP1 expression is a key factor that suppresses neoplastic transformation. We observed that either expression downregulation or mutation of MCPIP1 significantly increased its clonogenicity and altered the expression of cancer stem cell (CSC) markers and factors involved in epithelial-to-mesenchymal transition (EMT). In vivo studies demonstrated that MCPIP1 inactivation in normal epithelial cells leads to significant tumor formation and increased c-Myc phosphorylation, indicating enhanced cell proliferation. Proteomic analysis of mouse plasma revealed increased secretion of cancer-related proteins (CXCL13, CXCL16, and MMP2) in the MCPIP1-mutant group. Additionally, we revealed that MCPIP1 RNase activity regulates the expression of the stemness markers CD44 and CD133 and the phosphorylation of the c-Met receptor in tumor tissue samples. Mechanistically, via coimmunoprecipitation analysis, we found that the RNase activity of MCPIP1 controls CD44 expression and, consequently, that a strong interaction between CD44 and c-Met leads to c-Met activation. This regulation was confirmed in patient samples, in which increased CD44 expression correlated with ccRCC progression. These findings highlight the critical role of MCPIP1 RNase activity in modulating the c-Met/CD44 axis, thereby influencing stemness and tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.